title: Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals.
abstract: We previously conducted genome-wide association meta-analysis of systolic blood pressure, diastolic blood pressure, and hypertension in 29,136 people from 6 cohort studies in the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Here we examine associations of these traits with 30 gene regions encoding known antihypertensive drug targets. We find nominal evidence of association of ADRB1, ADRB2, AGT, CACNA1A, CACNA1C, and SLC12A3 polymorphisms with 1 or more BP traits in the Cohorts for Heart and Aging Research in Genomic Epidemiology genome-wide association meta-analysis. We attempted replication of the top meta-analysis single nucleotide polymorphisms for these genes in the Global BPgen Consortium (n=34,433) and the Women's Genome Health Study (n=23,019) and found significant results for rs1801253 in ADRB1 (Arg389Gly), with the Gly allele associated with a lower mean systolic blood pressure (β: 0.57 mm Hg; SE: 0.09 mm Hg; meta-analysis: P=4.7×10(-10)), diastolic blood pressure (β: 0.36 mm Hg; SE: 0.06 mm Hg; meta-analysis: P=9.5×10(-10)), and prevalence of hypertension (β: 0.06 mm Hg; SE: 0.02 mm Hg; meta-analysis: P=3.3×10(-4)). Variation in AGT (rs2004776) was associated with systolic blood pressure (β: 0.42 mm Hg; SE: 0.09 mm Hg; meta-analysis: P=3.8×10(-6)), as well as diastolic blood pressure (P=5.0×10(-8)) and hypertension (P=3.7×10(-7)). A polymorphism in ACE (rs4305) showed modest replication of association with increased hypertension (β: 0.06 mm Hg; SE: 0.01 mm Hg; meta-analysis: P=3.0×10(-5)). Two loci, ADRB1 and AGT, contain single nucleotide polymorphisms that reached a genome-wide significance threshold in meta-analysis for the first time. Our findings suggest that these genes warrant further studies of their genetic effects on blood pressure, including pharmacogenetic interactions.
authors: Framingham Heart Study, National Heart, Lung, and Blood Institute, Framingham, MA 01702, USA.
authors: Andrew D
authors: AD
authors: Johnson
authors: Christopher
authors: C
authors: Newton-Cheh
authors: Daniel I
authors: DI
authors: Chasman
authors: Georg B
authors: GB
authors: Ehret
authors: Toby
authors: T
authors: Johnson
authors: Lynda
authors: L
authors: Rose
authors: Kenneth
authors: K
authors: Rice
authors: Germaine C
authors: GC
authors: Verwoert
authors: Lenore J
authors: LJ
authors: Launer
authors: Vilmundur
authors: V
authors: Gudnason
authors: Martin G
authors: MG
authors: Larson
authors: Aravinda
authors: A
authors: Chakravarti
authors: Bruce M
authors: BM
authors: Psaty
authors: Mark
authors: M
authors: Caulfield
authors: Cornelia M
authors: CM
authors: van Duijn
authors: Paul M
authors: PM
authors: Ridker
authors: Patricia B
authors: PB
authors: Munroe
authors: Daniel
authors: D
authors: Levy
mesh_terms: D000483:Alleles; D000808:Angiotensinogen / Q000235:genetics; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics
chemical_list: C547787:ADRB1 protein, human; C534931:AGT protein, human; D000959:Antihypertensive Agents; D018342:Receptors, Adrenergic, beta-1; D000808:Angiotensinogen